← Patent-cliff monitor small molecule KISQALI RIBOCICLIB SUCCINATE
Loss of exclusivity October 2036 latest FDA-listed patent expiry
Company Novartis → See this company's full patent-cliff portfolio Drug detail Brand name KISQALI Active ingredient RIBOCICLIB SUCCINATE Strength EQ 200MG BASE Dosage form TABLET Route ORAL Modality Small molecule FDA approval March 2017 Marketing status RX
Listed patents Patent Expires Type 12064434*PED October 2036 — 10799506*PED October 2036 — 12419894*PED October 2036 — 10799506 April 2036 product 12064434 April 2036 product 12419894 April 2036 product 12544380*PED February 2035 — 12544379*PED February 2035 — 12544380 August 2034 use U-4405 12544379 August 2034 use U-3975 9193732*PED May 2032 — 9868739*PED May 2032 — 9193732 November 2031 substance, product 9868739 November 2031 use U-3266 8415355*PED September 2031 — 8415355 March 2031 substance, product 8685980*PED November 2030 — 8962630*PED June 2030 — 8685980 May 2030 substance, product 9416136*PED February 2030 — 8962630 December 2029 use U-3975 9416136 August 2029 use U-3975 8324225*PED December 2028 — 8324225 June 2028 substance, product
Regulatory exclusivity Code Expires PED March 2028 I-950 September 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.